Mürüvvet AKÇAY ÇELİK, HAVVA ERDEM, SONER ÇANKAYA, Yeliz ARICI

P16 staining patterns and their relationships with clinical parameters in cases of cervical intraepithelial neoplasia

The aim of this study is to investigate the contribution of the p16 immunohistochemical marker in the cervical intraepithelial neoplasia (CIN) cases in the distinction between CIN1, CIN2, CIN3 and the relationship of CINs with age, localization. CIN1, CIN2, CIN3 preparations of 2015 in the pathology department were retrospectively analyzed. New sections of 3 μm thickness were obtained on polylysine slides from paraffin blocks of these tissues. Samples with immunohistochemical staining with p16 were evaluated under a light microscope.p16 expression was semiquantitatively assessed according to staining intensity with 4 staining levels as score 0,1,2,3. As a result of the Kruskal-Wallis test, a significant difference was found between the scores in the CIN groups (p

PDF

___

1. Xing Y, Wang C, Wu J. Expression of geminin, p16, and Ki67 in cervical intraepithelial neoplasm and normal tissues.Medicine (Baltimore). 2017;96:7302.

2. Nayar R, Wibur DC. The Bethesda System for reporting cervical cytology: a historical perspective. Acta Cytol. 2017;61:359-72.

3. Darragh TM, Colgan TJ, Cox JT, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136:1266-97.

4. Martin CM, O’Leary JJ, Phil D. Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract Res Clin Obstet gynaecol. 2011;25:605–15.

5. Heatley MK.How should we grade CIN? Histopathology. 2002;40:377–80.

6. Alshenawy HA. Evaluation of p16, human papillomavirus capsid protein L1 and Ki-67 in cervical intraepithelial lesions: potential utility in diagnosis and prognosis. Pathol Res Pract. 2004;210:916–21.

7. Rouzier R. Management of CIN1. J Gynecol Obstet Biol R. 2008;1:114–20.

8. Baak JP, Kruse AJ, Robboy SJ, et al. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol. 2006;59:1017–28.

9. Prendiville W, Sankaranarayanan R. Colposcopy and treatment of cervical precancer. Lyon: IARC Technical Publication. 2017;131:28-32.

10. Rosa M, Mohammadi A. Cervical cytology and human papillomavirus testing in adolescent women: implications in management of a positive HPV test. Patholog Res Int. 2014;2014:165690.

11. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for humanpapillomavirus-related cervical neoplasia. Am J Surg Pathol. 2001;25:884–91.

12. Herrington CS. The terminology of pre-invasive cervical lesions in the UK cervical screening programme. Cytopathology. 2015;26:346–50.

13. Vesco KK, Whitlock EP, Eder M, et al. Risk factors and other epidemiological considerations for cervical cancer screening: a narrative review for the US. Preventive Services Task Force. Ann Intern Med. 2011;155:698-705.

14. Mishra GA, Pimple SA, Shastri SS. An overview of prevention and early detection of cervical cancer. Indian J Med Paediatr Oncol. 2011;32:125-32.

15. Liverani CA, Dig J, Clemente N, et al.Length but not transverse diameter of the excision specimen for high-grade cervical intraepithelial neoplasia (CIN 2–3) is a predictor of pregnancy outcome. Eur J Cancer Prev. 2016;25:416- 22.

16. Hawkes AP, Kronenberger CB, Mackenzie TD, et al. Cervical cancer screening: American college of preventive medicine practice policy statement. Am J Prev Med. 2016;12:342-4.

17. Liu Y, Lu Z, Xu R, et al. Comprehensive mapping of the human papilloma virus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology. Oncotarget. CV. 2016;7:5852-64.

18. Chen Z, Wang Y, Mi X, et al. Application of van-clear and xylenein the detection of cervical hTERC gene by fluorescence in situ hybridization. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016;41:367-73.

19. Nogueira MC, Guedes Neto Ede P, Rosa MW et al. Immunohistochemical expression of p16 and p53 in vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva. Pathol Oncol Res. 2006;12:153–7.

20. Léonard B, Kridelka F, Delbecque K, et al. A clinical and pathological overview of vulvar condyloma acuminatum, intraepithelial neoplasia, and squamous cell carcinoma. Biomed Res Int. 2014;2014:480573.

21. Lambert AF, Anshau F, Schmitt. p16 expression in cervical premalignant and malignant lesions. Exp Mol Pathol. 2006;80:192-6.

22. Klaes R, Friedrich T, Spitkovsky D, et al. Over expression of p16INK4a as a speciﬁc marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276–84.

23. Kalof AN, Evans MF, Simmons-Arnold L, et al. p16 INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. Am J Surg Pathol. 2005;29:674–9.

24. Volgareva G, Zavalishina L, Andreeva Y, et al. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer. 2004;4:58.

25. Lewis JS Jr. p16 Immunohisto chemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 2012;6:75–82.

26. Lorenzato M, Caudroy S, Bronner C, et al. Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions? Hum Pathol. 2005;36:1101–7.

27. U Sarma, Ira B, Alakananda D, et al. p16INK4a Expression in Cervical Lesions Correlates with Histologic Grading- a Tertiary Level Medical Facility Based Retrospective Study. Asian Pac J Cancer Prev. 2017;18:2643– 8.

28. Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505-27.

29. Mezei AK, Armstrong HL, Pedersen HN, et al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a Systematic review. Int J Cancer. 2017;141:437-46.

30. Östör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186-92.

31. Vink MA, Bogaards JA, van Kemenade FJ, et al. Clinical progression of highgrade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol. 2013;178:1161-9.

32. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9:425-34.

33. Negri G, Egarter-Vigl E, Kasal A, et al. P16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors. Am J Surg Pathol. 2003;27:187–93.

34. Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO Classification of Tumours of Female Reproductive Organs. Geneva, Switzerland: World Health Organization; 2014.

35. Kanjana K, Jakkapan K, Siriwan T, et al. Expression of the p16 and Ki67 in Cervical Squamous Intraepithelial Lesions and Cancer. Asian Pac J Cancer Prev.2016;17:3201-6.

36. Doeberitz MVK. New molecular tools for efficient screening of cervical cancer. Dis Markers. 2001;17:123-8.

37. Gondos B, Marshall D and Ostergard. Endocervical cells in cervical smears. Am. J. Obstet. Gynecol.1972;15:833–4.

38. Foote FW Jr, Stewart FW. The anatomical distribution of intraepithelial epidermoid carcinomas of the cervix. Cancer. 1948;1:431–40.

39. He G, Li H, Lin H, et al. Topographical distribution pattern of cervical intraepithelial neoplasia across the cervix. J Int Med Res. 2012;40:1897– 903.

40. Zhao Y, Chang IJ, Zhao F, et al. Distribution of cervical intraepithelial neoplasia on the cervix in Chinese women: pooled analysis of 19 population based screening studies. BMC Cancer. 2015;15:485.